GSK to stop developing cough drug after missing main target

• Camlipixant's 50mg dose successfully reduced 24-hour cough frequency versus placebo at 12 weeks when taken twice daily
• The drug failed to reach statistical significance for the same primary endpoint at week 24, prompting GSK to halt further development
• The discontinuation affects treatment options for refractory chronic cough, a condition with limited therapeutic alternatives

GSK Halts Chronic Cough Drug Development After Late-Stage Trial Failure

GSK announced on Friday, July 17, that it will discontinue development of camlipixant, an experimental treatment for refractory chronic cough, following mixed results in a late-stage clinical trial.

Trial Results:

The 50 mg dose of camlipixant achieved its primary endpoint at the 12-week mark, successfully reducing 24-hour cough frequency compared to placebo when administered twice daily. However, the drug failed to reach statistical significance for the same primary goal at week 24, the trial's longer-term measurement point.

Market Implications:

This development represents a setback for GSK's respiratory portfolio and its efforts to address refractory chronic cough, a condition with limited treatment options. The decision to halt development suggests the company determined the drug's risk-benefit profile and commercial viability were insufficient to warrant continued investment, despite the positive 12-week data.

The failure at the 24-week endpoint raises questions about the drug's durability and long-term efficacy, which are critical factors for chronic condition treatments. This discontinuation will likely prompt GSK to reallocate resources to other pipeline candidates.

Company Impact:

While specific financial impacts were not disclosed, the termination of a late-stage program typically results in write-offs of development costs and represents lost potential revenue opportunity in the chronic cough market. Investors will be watching for GSK's strategy to fill this gap in its respiratory franchise and whether the company has alternative assets targeting similar patient populations.

The announcement adds to the pharmaceutical industry's high clinical trial failure rate, particularly in late-stage development where efficacy must be sustained over longer periods.